Patents by Inventor Juan C. Jaen
Juan C. Jaen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10342781Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are diazole lactam derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated disease, and as controls in assays for the identification of competitive CCR1 antagonists.Type: GrantFiled: July 25, 2017Date of Patent: July 9, 2019Assignee: ChemoCentryx, Inc.Inventors: Xi Chen, Dean R. Dragoli, Pingchen Fan, Juan C. Jaen, Yandong Li, Jay P. Powers, Viengkham Malathong, Sreenivas Punna, Hiroko Tanaka, Penglie Zhang
-
Publication number: 20180071257Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are diazole lactam derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated disease, and as controls in assays for the identification of competitive CCR1 antagonists.Type: ApplicationFiled: July 25, 2017Publication date: March 15, 2018Inventors: Xi CHEN, Dean R. DRAGOLI, Pingchen FAN, Juan C. JAEN, Yandong LI, Jay P. POWERS, Viengkham MALATHONG, Sreenivas PUNNA, Hiroko TANAKA, Penglie ZHANG
-
Patent number: 9750722Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are diazole lactam derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated disease, and as controls in assays for the identification of competitive CCR1 antagonists.Type: GrantFiled: October 8, 2015Date of Patent: September 5, 2017Assignee: CHEMOCENTRYX, INC.Inventors: Xi Chen, Dean R. Dragoli, Pingchen Fan, Juan C. Jaen, Yandong Li, Jay P. Powers, Viengkham Malathong, Sreenivas Punna, Hiroko Tanaka, Penglie Zhang
-
Publication number: 20160193185Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are diazole lactam derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated disease, and as controls in assays for the identification of competitive CCR1 antagonists.Type: ApplicationFiled: October 8, 2015Publication date: July 7, 2016Inventors: Xi CHEN, Dean R. DRAGOLI, Pingchen FAN, Juan C. JAEN, Yandong LI, Jay P. POWERS, Viengkham MALATHONG, Sreenivas PUNNA, Hiroko TANAKA, Penglie ZHANG
-
Patent number: 9169248Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are diazole lactam derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated disease, and as controls in assays for the identification of competitive CCR1 antagonists.Type: GrantFiled: December 20, 2013Date of Patent: October 27, 2015Assignee: ChemoCentryx, Inc.Inventors: Xi Chen, Dean R. Dragoli, Pingchen Fan, Juan C. Jaen, Yandong Li, Jay P. Powers, Viengkham Malathong, Sreenivas Punna, Hiroko Tanaka, Penglie Zhang
-
Patent number: 8853202Abstract: Compounds having formula I, or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with a pharmaceutically acceptable excipient.Type: GrantFiled: May 12, 2010Date of Patent: October 7, 2014Assignee: ChemoCentryx, Inc.Inventors: Xi Chen, Dean R. Dragoli, Pingchen Fan, Mark M. Gleason, Juan C. Jaen, Lianfa Li, Jeffrey P. McMahon, Jay Powers, Yibin Zeng, Penglie Zhang, Junfa Fan
-
Publication number: 20140179733Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are diazole lactam derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated disease, and as controls in assays for the identification of competitive CCR1 antagonists.Type: ApplicationFiled: December 20, 2013Publication date: June 26, 2014Applicant: ChemoCentryx, Inc.Inventors: Xi Chen, Dean R. Dragoli, Pingchen Fan, Juan C. Jaen, Yandong Li, Jay P. Powers, Viengkham Malathong, Sreenivas Punna, Hiroko Tanaka, Penglie Zhang
-
Patent number: 8288373Abstract: Compounds having formula I, or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with a pharmaceutically acceptable excipient.Type: GrantFiled: November 4, 2009Date of Patent: October 16, 2012Assignee: Chemocentryx, Inc.Inventors: Xi Chen, Pingchen Fan, Mark M. Gleason, Juan C. Jaen, Lianfa Li, Jeffrey P. McMahon, Jay Powers, Yibin Zeng, Penglie Zhang
-
Patent number: 7939551Abstract: The present invention provides pharmaceutical compositions and methods for the treatment of diabetes mellitus using combination therapy. The compositions relate to a compound of Formula I and an antidiabetic agent such as sulfonylureas, biguanides, glitazones, ?-glucosidase inhibitors, potassium channel antagonists, aldose reductase inhibitors, glucagon antagonists, activators of RXR, insulin therapy or other anti-obesity agent. The methods include the administration of the combination of compound of Formula I with antidiabetic agent where the two components are delivered in a simultaneous manner, where the compound of Formula I is administered first, followed by the antidiabetic agent, as well as wherein the antidiabetic agent is delivered first followed by the compound of Formula I.Type: GrantFiled: October 26, 2005Date of Patent: May 10, 2011Assignee: Amgen Inc.Inventors: Juan C. Jaen, Jin-Long Chen
-
Publication number: 20110014121Abstract: Compounds having formula I, or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with a pharmaceutically acceptable excipient.Type: ApplicationFiled: March 29, 2010Publication date: January 20, 2011Applicant: ChemoCentryx, Inc.Inventors: Xi Chen, Pingchen Fan, Mark M. Gleason, Juan C. Jaen, Lianfa Li, Jeffrey P. McMahon, Jay Powers, Yibin Zeng, Penglie Zhang
-
Publication number: 20100311712Abstract: Compounds having formula I, or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with a pharmaceutically acceptable excipient.Type: ApplicationFiled: May 12, 2010Publication date: December 9, 2010Applicant: ChemoCentryx, Inc.Inventors: Xi CHEN, Dean R. DRAGOLI, Pingchen FAN, Mark M. GLEASON, Juan C. JAEN, Lianfa LI, Jeffrey P. MCMAHON, Jay POWERS, Yibin ZENG, Penglie ZHANG, Junfa FAN
-
Publication number: 20100150831Abstract: Compounds having formula I, or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with a pharmaceutically acceptable excipient.Type: ApplicationFiled: November 4, 2009Publication date: June 17, 2010Applicant: ChemoCentryx, Inc.Inventors: Xi Chen, Pingchen Fan, Mark M. Gleason, Juan C. Jaen, Lianfa Li, Jeffrey P. McMahon, Jay Powers, Yibin Zeng, Penglie Zhang
-
Patent number: 7635695Abstract: Compounds, compositions and methods that are useful in the treatment of inflammatory, immunoregulatory, metabolic, infectious and cell proliferative diseases or conditions are provided herein. In particular, the invention provides compounds which modulate the expression and/or function of proteins involved in inflammation, metabolism, infection and cell proliferation. The subject compounds contain a fused heterobicyclic ring.Type: GrantFiled: February 21, 2007Date of Patent: December 22, 2009Assignee: Amgen Inc.Inventors: Simon A. Burkitt, Mario G. Cardozo, Timothy D. Cushing, Michael R. DeGraffenreid, Christopher N. Farthing, Xiaolin Hao, Juan C. Jaen, Xian Yun Jiao, David J. Kopecky, Marc Labelle, Sarah E. Lively, Dustin L. McMinn, Sven P. Rasmussen, Youngsook Shin, Marie-Louise Smith, Andrew Smith
-
Patent number: 7572783Abstract: The present invention relates to the compounds of Formula I, their preparation and pharmaceutical compositions comprising them. The compounds and pharmaceutical compositions are useful, for example, for the treatment and prevention of obesity, obesity-related disorders and eating disorders.Type: GrantFiled: August 12, 2005Date of Patent: August 11, 2009Assignee: Amgen Inc.Inventors: Xi Chen, Xiaoqi Chen, Richard Victor Connors, Kang Dai, Ying Fu, Juan C. Jaen, Yong-Jae Kim, Leping Li, Mike E. Lizarzaburu, Jeffrey T. Mihalic, Stephen J. Shuttleworth
-
Patent number: 7358267Abstract: Compounds, compositions and methods are provided that are useful in the treatment or prevention of a condition or disorder mediated by an uncoupling protein. In particular, the compounds of the invention modulate the expression and/or activity of UCP3.Type: GrantFiled: June 27, 2002Date of Patent: April 15, 2008Assignee: Amgen Inc.Inventors: M. Catherine Amaral, Jin-Long Chen, Juan C. Jaen, David N. Johnston, Paul Rafferty
-
Patent number: 7199119Abstract: Compounds, compositions and methods that are useful in the treatment of inflammatory, immunoregulatory, metabolic, infectious and cell proliferative diseases or conditions are provided herein. In particular, the invention provides compounds which modulate the expression and/or function of proteins involved in inflammation, metabolism, infection and cell proliferation. The subject compounds contain a fused heterobicyclic ring.Type: GrantFiled: September 19, 2003Date of Patent: April 3, 2007Assignee: Amgen Inc.Inventors: Simon A. Burkitt, Mario G. Cardozo, Timothy D. Cushing, Michael R. DeGraffenreid, Christopher N. Farthing, Xiaolin Hao, Juan C. Jaen, XianYun Jiao, David J. Kopecky, Marc Labelle, Sarah E. Lively, Dustin L. McMinn, Sven P. Rasmussen, Youngsook Shin, Marie-Louise Smith, Andrew Smith
-
Patent number: 7186841Abstract: Compounds, compositions and methods that are useful in the treatment of inflammatory, immunoregulatory, metabolic and cell proliferative conditions or diseases are provided herein. In particular, the invention provides compounds which modulate the expression and/or function of proteins involved in inflammation, metabolism and cell proliferation. The subject compounds contain fused carbocyclic or heterocyclic rings.Type: GrantFiled: August 26, 2004Date of Patent: March 6, 2007Assignees: Amgen Inc., Syntex (U.S.A.) LLCInventors: Michelle F. Browner, David L. Clark, Timothy D. Cushing, Xiaolin Hao, Ronald C. Hawley, Xiao He, Juan C. Jaen, Sharada S. Labadie, Marie-Louise Smith, Francisco X. Talamas, Nigel P. C. Walker, Marc Labelle
-
Patent number: 7176314Abstract: Compounds, compositions and methods that are useful in the treatment of inflammatory, immunoregulatory, metabolic and cell proliferative conditions or diseases are provided herein. In particular, the invention provides compounds which modulate the expression and/or function of proteins involved in inflammation, metabolism and cell proliferation. The subject compounds contain quinoline or quinazoline rings.Type: GrantFiled: December 4, 2002Date of Patent: February 13, 2007Assignee: Amgen, Inc.Inventors: Timothy D. Cushing, Xiao He, Marie-Louise Smith, Michael R. DeGraffenreid, Jay Powers, Craig S. Tomooka, David L. Clark, Xiaolin Hao, Juan C. Jaen, Marc Labelle, Nigel P. C. Walker, Adrian L. Gill, Francisco X. Talamas, Sharada Labadie
-
Patent number: 6846834Abstract: Compounds, compositions and methods that are useful in the treatment of inflammatory, immunoregulatory, metabolic and cell proliferative conditions or diseases are provided herein. In particular, the invention provides compounds which modulate the expression and/or function of proteins involved in inflammation, metabolism and cell proliferation. The subject compounds contain fused carbocyclic or heterocyclic rings.Type: GrantFiled: October 23, 2001Date of Patent: January 25, 2005Assignees: Amgen Inc., Syntex (U.S.A.) LLCInventors: Michelle F. Browner, David L. Clark, Timothy D. Cushing, Xiaolin Hao, Ronald C. Hawley, Xiao He, Juan C. Jaen, Sharada S. Labadie, Marie-Louise Smith, Francisco X. Talamas, Nigel P. C. Walker, Marc Labelle
-
Patent number: 6835726Abstract: Compounds and compositions are provided which are useful for the treatment of viral infections, particularly human Cytomegalovirus infection. The compounds include novel pyrimidine-based derivatives.Type: GrantFiled: January 24, 2003Date of Patent: December 28, 2004Assignee: Amgen Inc.Inventors: Timothy D. Cushing, Heather L. Mellon, Juan C. Jaen, John A. Flygare, Shi-Chang Miao, Xiaoqi Chen, Jay P. Powers